Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Fingolimod
Novartis Pharmaceuticals
Multiple Sclerosis (MS)
1 trial -
Fulvestrant
Novartis Pharmaceuticals
Breast Cancer
1 trial -
Fulvestrant
Novartis Pharmaceuticals
Metastatic Breast Cancer
1 trial -
Glycopyrronium bromide
Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
1 trial -
INCLISIRAN, -
Novartis Pharmaceuticals
Familial hypercholsterolemia
1 trial -
IPTACOPAN
Novartis Pharmaceuticals
Atypical hemolytic uremic syndrome
1 trial -
IPTACOPAN
Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome (aHUS)
1 trial -
IPTACOPAN
Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome (aHUS)
1 trial -
IPTACOPAN HYDROCHLORIDE
Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
1 trial -
IPTACOPAN, LNP023
Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria (PNH)
1 trial -
Ianalumab
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
1 trial -
Ianalumab
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia
2 trials -
Inclisiran
Novartis Pharmaceuticals
Familial Hypercholesterolemia - Heterozygous
1 trial -
Indacaterol 150 μg
Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
Indacaterol 150 μg
Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
2 trials -
Investigators choice of SoC
Novartis Pharmaceuticals
Prostate Cancer
1 trial -
Iptacopan
Novartis Pharmaceuticals
Atypical Hemolytic Uremic Syndrome
1 trial -
JDQ443
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
1 trial -
LCZ696 (sacubitril/valsartan)
Novartis Pharmaceuticals
Acute Myocardial Infarction
1 trial -
LMF237 50/250 mg
Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
1 trial -
LNP023
Novartis Pharmaceuticals
Primary IgA Nephropathy
1 trial -
LOU064
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
1 trial -
LOU064 (blinded)
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
1 trial -
Lapatinib
Novartis Pharmaceuticals
Neoplasms, Breast
2 trials
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.